H.C. Wainwright Downgrades Mirna, Inc. (MIRN) to Neutral

H.C. Wainwright downgraded Mirna, Inc. (NASDAQ: MIRN) from Buy to Neutral with a price target of $2.00 (from $6.00). The change follows news the company halted its MRX34 trial.

"Following the voluntary stop of the MRX34 trial, we are removing MRX34 sales from our estimates and downgrading MIRN from a Buy to Neutral. We believe Mirna may yet develop a compelling microRNA-based oncology drug, but we are uncertain about the delivery technology it may use and the miRNA target it may pursue. That said, we like that Mirna has a three-year cash runway to ruminate and refine its clinical development plans," said analyst Shaunak Deepak.

For an analyst ratings summary and ratings history on Mirna, Inc. click here. For more ratings news on Mirna, Inc. click here.

Shares of Mirna, Inc. closed at $1.96 yesterday.

You May Also Be Interested In

• HSBC Downgrades Feng Tay Enterprises (9910:TT) to Hold
• Johnson Matthey PLC (JMAT:LN) (JMPLY) PT Raised to GBP21.70 at Barclays
• AvidBank Holdings Inc. (AVBH) PT Lowered to $23 at Piper Sandler